92 related articles for article (PubMed ID: 14990053)
21. Notch signaling inhibits the growth of the human chronic myeloid leukemia cell line K562.
Yin DD; Fan FY; Hu XB; Hou LH; Zhang XP; Liu L; Liang YM; Han H
Leuk Res; 2009 Jan; 33(1):109-14. PubMed ID: 18687467
[TBL] [Abstract][Full Text] [Related]
22. Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562.
Zhang K; Xu J; Huang X; Wu L; Wen C; Hu Y; Su Y; Chen Y; Zhang Z
Cancer Chemother Pharmacol; 2007 Sep; 60(4):581-7. PubMed ID: 17435997
[TBL] [Abstract][Full Text] [Related]
23. Disialoganglioside GD3 synthase expression recruits membrane transglutaminase 2 during erythroid differentiation of the human chronic myelogenous leukemia K562 cells.
Kang SK; Kim YS; Kong YJ; Song KH; Chang YC; Park YG; Ko JH; Lee YC; Kim CH
Proteomics; 2008 Aug; 8(16):3317-28. PubMed ID: 18690648
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells.
Chen JY; Wang MC; Hung WC
Leuk Res; 2009 Nov; 33(11):1520-4. PubMed ID: 19329185
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes.
Ohba H; Zhelev Z; Bakalova R; Ewis A; Omori T; Ishikawa M; Shinohara Y; Baba Y
Cancer; 2004 Sep; 101(6):1390-403. PubMed ID: 15368327
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90.
Wu LX; Xu JH; Huang XW; Zhang KZ; Wen CX; Chen YZ
Acta Pharmacol Sin; 2006 Jun; 27(6):694-9. PubMed ID: 16723087
[TBL] [Abstract][Full Text] [Related]
28. [Using real-time polymerase chain reaction to quantitate bcr-abl mRNA].
Liu JX; Liu JL; Wang GJ
Ai Zheng; 2006 Nov; 25(11):1447-9. PubMed ID: 17094919
[TBL] [Abstract][Full Text] [Related]
29. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Chen R; Gandhi V; Plunkett W
Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
[TBL] [Abstract][Full Text] [Related]
30. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
31. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
Ruan GR; Qin YZ; Chen SS; Li JL; Ma X; Chang Y; Wang YZ; Fu JY; Liu YR
Leuk Res; 2006 Sep; 30(9):1159-65. PubMed ID: 16507320
[TBL] [Abstract][Full Text] [Related]
32. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
Bártová E; Harnicarová A; Pacherník J; Kozubek S
Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
[TBL] [Abstract][Full Text] [Related]
33. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
Desplat V; Lagarde V; Belloc F; Chollet C; Leguay T; Pasquet JM; Praloran V; Mahon FX
Cytometry A; 2004 Nov; 62(1):35-45. PubMed ID: 15468123
[TBL] [Abstract][Full Text] [Related]
34. The modulation of radiation-induced cell death by genistein in K562 cells: activation of thymidine kinase 1.
Jeong MH; Jin YH; Kang EY; Jo WS; Park HT; Lee JD; Yoo YJ; Jeong SJ
Cell Res; 2004 Aug; 14(4):295-302. PubMed ID: 15353126
[TBL] [Abstract][Full Text] [Related]
35. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
[TBL] [Abstract][Full Text] [Related]
36. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
[TBL] [Abstract][Full Text] [Related]
37. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
[TBL] [Abstract][Full Text] [Related]
38. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
[TBL] [Abstract][Full Text] [Related]
39. Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells.
Wang X; Ren J; Qu X
ChemMedChem; 2008 Jun; 3(6):940-5. PubMed ID: 18286553
[TBL] [Abstract][Full Text] [Related]
40. Expression of cyclins D1, D2, and D3 and Ki-67 in Leukemia.
Jaroslav P; Martina H; Jirí S; Hana K; Petr S; Tomás K; Julius M; Cedrik H
Leuk Lymphoma; 2005 Nov; 46(11):1605-1612. PubMed ID: 16334487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
